RogerStuppMD

Neuro-Oncology

Chief, Division of Neuro-Oncology and Medical Director, Malnati Brain Tumor Institute, Departments of Neurology and Neurological Surgery and Division of Hematology/Oncology; Associate Director, Lurie Comprehensive Cancer Center

Join to view full profile

Dr. Stupp is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Stupp's full profile

Already have an account?

Office
676 N. St. Clair Street
Suite 2210
Chicago, IL 60611
Phone+1 312-694-1306

Fax+1 312-695-4430

Education & Training

University of Zurich Faculty of MedicineClass of 1987

Certifications & Licensure

IL State Medical License 2016 - 2026

Clinical Trials

Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma Start of enrollment: 2020 Oct 29
Recruiting
Phase 1, Phase 2
A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM Start of enrollment: 2022 Jul 30
ACTIVE_NOT_RECRUITING
EARLY_PHASE1
Roles: Contact
Trotabresib in Combination With Vinorelbine and Radiation Therapy for the Treatment of HER2+ Breast Cancer With Central Nervous System or Leptomeningeal Metastasis Start of enrollment: 2023 Dec 31
Withdrawn
Phase 1
Roles: Principal Investigator, Contact
Repeated Neural Stem Cell Based Virotherapy for Newly Diagnosed High Grade Glioma Start of enrollment: 2025 Apr 15
NOT_YET_RECRUITING
PHASE1
Roles: Contact, Principal Investigator
Multiple Doses of Neural Stem Cell Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas Start of enrollment: 2023 May 02
Recruiting
Phase 1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Temozolomide chemotherapy for patients with newly diagnosed glioblastoma in the CENTRIC EORTC 26071-22072 and CORE trials: Does time of administration matter?
Marjolein Geurts, Luzia Berchtold, Franz Koenig, Burt Nabors, David A Reardon
Neuro-Oncology Practice. 2025-04-01
High Dimensional Proteomic Multiplex Imaging of the Central Nervous System Using the COMETSystem.
Hinda Najem, Sebastian Pacheco, Jillyn Turunen, Shashwat Tripathi, Alicia Steffens
Biorxiv. 2025-02-19
Rethinking metastatic brain cancer as a CNS disease.
Jawad Fares, Edgar Petrosyan, Crismita Dmello, Rimas V Lukas, Roger Stupp
The Lancet. Oncology. 2025-02-01

Press Mentions

Blood-Brain Barrier Disruption Reveals Genetic and Structural Changes in Neurological DiseasesFebruary 24th, 2025
New Glioblastoma Treatment Reaches Human Brain Tumor and Helps Immune Cells Recognize Cancer CellsJune 6th, 2024
Chemotherapy Drug Reaches Brain in Humans for First TimeMay 3rd, 2023
Join now to see all